Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy

Tang, Hui; Zaroudi, Maryam; Zhu, Yuli; Cheng, Alex; Qin, Lei; Zhang, Bin; Liu, Ying

doi:10.1016/j.jconrel.2023.09.005

Journal of Controlled Release

2023

DOI: 10.1016/j.jconrel.2023.09.005

|View full text |Cite

Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy

Hui Tang,

Maryam Zaroudi,

Yuli Zhu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A recent advancement in the delivery of CAR‐T: Use lyophilized lymph nodes

Du,

Cheng,

Zhao

2024

MedComm – Biomaterials and Applications

View full text Add to dashboard Cite

A recent advancement in the delivery of CAR‐T: Use lyophilized lymph nodes

Du,

Cheng,

Zhao

2024

MedComm – Biomaterials and Applications

View full text Add to dashboard Cite

CAR-T cell therapy: Advances in digestive system malignant tumors

Xu,

Wu,

Pan

et al. 2024

Molecular Therapy: Oncology

View full text Add to dashboard Cite

Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers

Gu,

Zhang,

Zhou

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes for tumors, especially for hematological malignancies. However, extending the duration of remission, reduction of relapse for hematological malignancies and improvement of the anti-tumor efficacy for solid tumors are challenges for CAR-T cells immunotherapy. Besides the endeavors to enhance the functionality of CAR-T cell per se, optimization of the infusion and delivery strategies facilitates the breakthrough of the hurdles that limited the efficacy of this cancer immunotherapy. Here, we summarized the infusion and delivery strategies of CAR-T cell therapies under pre-clinical study, clinical trials and on-market status, through which the improvements of safety and efficacy for hematological and solid tumors were analyzed. Of note, novel infusion and delivery strategies, including local-regional infusion, biomaterials bearing the CAR-T cells and multiple infusion technique, overcome many limitations of CAR-T cell therapy. This review provides hints to determine infusion and delivery strategies of CAR-T cell cancer immunotherapy to maximize clinical benefits.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy

Cited by 3 publications

References 32 publications

A recent advancement in the delivery of CAR‐T: Use lyophilized lymph nodes

A recent advancement in the delivery of CAR‐T: Use lyophilized lymph nodes

CAR-T cell therapy: Advances in digestive system malignant tumors

Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers

Contact Info

Product

Resources

About